Latest Clinical Trials
Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC 3D Medicines (Sichuan) Co., Ltd. NA
COMPLETED
(Sep 1, 2026)
PHASE3 TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers Tizona Therapeutics, Inc NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE) Rutgers, The State University of New Jersey NA
RECRUITING
(Sep 1, 2026)
PHASE2 CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer Holy Stone Healthcare Co., Ltd NA
SUSPENDED
(Sep 1, 2026)
PHASE2 Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI Assistance Publique - Hôpitaux de Paris NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Hoffmann-La Roche NA
RECRUITING
(Sep 1, 2026)
PHASE1 CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen CytoDyn, Inc. NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL Hoffmann-La Roche NA
RECRUITING
(Sep 1, 2026)
PHASE2 Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer. Gruppo Oncologico del Nord-Ovest NA
RECRUITING
(Sep 1, 2026)
PHASE3 Perioperative Treatment of Hepatoid Adenocarcinoma of Stomach Peking University Cancer Hospital & Institute NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer Astellas Pharma Global Development, Inc. NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Guangzhou Lupeng Pharmaceutical Company LTD. NA
RECRUITING
(Sep 1, 2026)
PHASE1 A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC BeOne Medicines NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Shanghai Junshi Bioscience Co., Ltd. NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer University of Oklahoma NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE1 Clinical Studies of Gemcitabine-Oxaliplatin Gustave Roussy, Cancer Campus, Grand Paris NA
COMPLETED
(Aug 1, 2026)
PHASE2 Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy Gustave Roussy, Cancer Campus, Grand Paris NA
COMPLETED
(Aug 1, 2026)
PHASE2 D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma Hospices Civils de Lyon NA
COMPLETED
(Aug 1, 2026)
PHASE3 Short RT Versus RCT,Followed by Chemo and Organ Preservation for Interm and High-risk Rectal Cancer Patients Prof. Dr. med. Claus Rödel NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence Gruppo Oncologico del Nord-Ovest NA
COMPLETED
(Aug 1, 2026)
PHASE2 A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Hoffmann-La Roche NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102) Cancer Institute and Hospital, Chinese Academy of Medical Sciences NA
COMPLETED
(Aug 1, 2026)
PHASE2 A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer Innovent Biologics (Suzhou) Co. Ltd. NA
TERMINATED
(Aug 1, 2026)
PHASE1 Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Wake Forest University Health Sciences NA
RECRUITING
(Aug 1, 2026)
PHASE2 QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors Eastern Hepatobiliary Surgery Hospital NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer Ruijin Hospital NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma City of Hope Medical Center NA
RECRUITING
(Aug 1, 2026)
PHASE2 FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer Oncolytics Biotech NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) EMD Serono Research & Development Institute, Inc. NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Sinocelltech Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE3 Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma National Cancer Center, Japan NA
RECRUITING
(Aug 1, 2026)
PHASE2 Adjuvant Therapy for Potentially Immunotherapy-Responsive Gastric or Gastroesophageal Junction Adenocarcinoma The First Affiliated Hospital with Nanjing Medical University NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma The First Affiliated Hospital of Soochow University NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer Haisco Pharmaceutical Group Co., Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Centre Hospitalier Universitaire Dijon NA
RECRUITING
(Jul 1, 2026)
PHASE3 A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Hoffmann-La Roche NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors Seagen, a wholly owned subsidiary of Pfizer NA
RECRUITING
(Jul 1, 2026)
PHASE1 Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma Tongji Hospital NA
RECRUITING
(Jul 1, 2026)
PHASE2 Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma Fudan University NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1) St. Olavs Hospital NA
RECRUITING
(Jul 1, 2026)
PHASE2 Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial Shanghai Pudong Hospital NA
RECRUITING
(Jul 1, 2026)
PHASE2 AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas American Association for Cancer Research NA
RECRUITING
(Jul 1, 2026)
PHASE2 A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL Hutchmed NA
RECRUITING
(Jul 1, 2026)
PHASE3 SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer The First Affiliated Hospital with Nanjing Medical University NA
RECRUITING
(Jul 1, 2026)
PHASE2 A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma The First Affiliated Hospital of Soochow University NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Sacituzumab Tirumotecan (MK-2870) in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-Based Combination Therapy National Cancer Center, Japan NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Multi-Cohort Study of Zeprumetostat Combinations for Relapsed/Refractory PTCL Tianjin Medical University Cancer Institute and Hospital NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Neoadjuvant Propranolol Plus SOX and Toripalimab for Locally Advanced Gastric/GEJ Adenocarcinoma Ting Liu NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Phase 1b Dose Escalation Study of Intravenous JX-594 in Metastatic, Refractory Colorectal Carcinoma Jennerex Biotherapeutics NA
COMPLETED
(Jun 1, 2026)
PHASE1 Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1 Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1 Zhejiang University NA
RECRUITING
(Jun 1, 2026)
PHASE3 Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab Taylor Brooks NA
RECRUITING
(Jun 1, 2026)
PHASE1 Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest NA
RECRUITING
(Jun 1, 2026)
PHASE2 Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma. Federation Francophone de Cancerologie Digestive NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Savolitinib Plus Cetuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type Metastatic Colorectal Cancer Fudan University NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma Shanghai Zhongshan Hospital NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer University of Texas Southwestern Medical Center NA
COMPLETED
(May 1, 2026)
PHASE2 BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours Bold Therapeutics, Inc. NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Genmab NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
COMPLETED
(May 1, 2026)
PHASE3 Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma University Hospital, Grenoble NA
COMPLETED
(May 1, 2026)
PHASE1 Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma CStone Pharmaceuticals NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 SAMe in Prevention of Oxaliplatin-associated Liver Injury Cedars-Sinai Medical Center NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma University of California, San Diego NA
RECRUITING
(May 1, 2026)
PHASE2 mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer Sun Yat-sen University NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China Genmab NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer J-Pharma Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE3 A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab Oncolytics Biotech NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1, PHASE2 IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Innovent Biologics (Suzhou) Co. Ltd. NA
RECRUITING
(May 1, 2026)
PHASE2 Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarcinoma Ruijin Hospital NA
RECRUITING
(May 1, 2026)
PHASE2 HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven) Binkui Li NA
RECRUITING
(May 1, 2026)
PHASE3 To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors Shenzhen Xinhe Biomedical NA
RECRUITING
(May 1, 2026)
PHASE1 A Clinical Study of SHR-1701 Combined With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Siewert Type II Adenocarcinoma of the Esophagogastric Junction Hebei Medical University Fourth Hospital NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer First Affiliated Hospital of Zhejiang University NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy. UNICANCER NA
SUSPENDED
(Apr 1, 2026)
PHASE2 Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma ADC Therapeutics S.A. NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer Onconic Therapeutics Inc. NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung University Health Network, Toronto NA
RECRUITING
(Apr 1, 2026)
PHASE1 Study Evaluating the Efficacy of the myDIET Software Tool in the Nutritional Management of Patients With Localized and Resectable Gastric or Esogastric Junction Cancer. Centre Leon Berard NA
RECRUITING
(Apr 1, 2026)
PHASE2 TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma Guohui Xu NA
RECRUITING
(Apr 1, 2026)
PHASE3 Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma Sun Yat-sen University NA
RECRUITING
(Apr 1, 2026)
PHASE2 MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma Washington University School of Medicine NA
RECRUITING
(Apr 1, 2026)
PHASE1 Clinical Study of Low-dose Interval Radiotherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma Shandong Provincial Hospital NA
RECRUITING
(Apr 1, 2026)
PHASE2 Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJ Cancer Institute and Hospital, Chinese Academy of Medical Sciences NA
RECRUITING
(Apr 1, 2026)
PHASE2 HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03) Fudan University NA
RECRUITING
(Apr 1, 2026)
PHASE2 A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression Yongxu Jia NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma Sun Yat-sen University NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer Beijing Friendship Hospital NA
RECRUITING
(Apr 1, 2026)
PHASE2 Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer Shanghai Shengdi Pharmaceutical Co., Ltd NA
RECRUITING
(Apr 1, 2026)
PHASE3 Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell Lymphoma Patients Eligible for CAR-T-cell Therapy With a Glofitamab-based Induction and Consolidation Concept Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma Beijing Tongren Hospital NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer Institut du Cancer de Montpellier - Val d'Aurelle NA
COMPLETED
(Mar 1, 2026)
PHASE1, PHASE2 Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer Rutgers, The State University of New Jersey NA
RECRUITING
(Mar 1, 2026)
PHASE2 Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma Northwell Health NA
RECRUITING
(Mar 1, 2026)
PHASE2 Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer Sun Yat-sen University NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE2 A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma Fudan University NA
RECRUITING
(Mar 1, 2026)
PHASE2 Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases Ruijin Hospital NA
RECRUITING
(Mar 1, 2026)
PHASE2 Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC The First Affiliated Hospital with Nanjing Medical University NA
RECRUITING
(Mar 1, 2026)
PHASE2 
